{"success":true,"data":{"pressRelease":{"id":"98138","rtpr_id":"nGNXc0yjzC","ticker":"REGN","exchange":"NASDAQ","all_tickers":["REGN"],"title":"The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN","author":"Globe Newswire","published_at":"2026-07-24T16:53:14.110Z","article_body":"NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the\nfollowing notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ:\nREGN).\n\nShareholders who purchased shares of REGN during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointment.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCONTACT US HERE:\n\nhttps://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form-2/?id=195838&from=3 \n\nCLASS PERIOD: August 1, 2025 to May 15, 2026\n\nALLEGATIONS: According to the complaint, defendants provided overwhelmingly\npositive statements to investors while, at the same time, disseminating\nmaterially false and misleading statements and/or concealing material adverse\nfacts concerning the true state of Regeneron’s Phase III Fianlimab-Libtayo\nStudy; notably, that its preliminary statistical assumptions were\nfundamentally flawed, that the active treatment arm was failing to achieve\nmeaningful clinical differentiation over standard therapies, and that the\ntrial would ultimately fail to reach statistical significance on its primary\nendpoint even without overperformance of the control arm. On April 29, 2026,\nduring Regeneron’s first quarter earnings call, defendants disclosed the\nPhase III Fianlimab-Libtayo Study had been altered, expanding the number of\npatients in the study eligible for “analysis of progression-free\nsurvival.” Following this news, the price of Regeneron’s common stock\ndeclined dramatically. From a closing market price of $731.77 per share on\nApril 28, 2026, Regeneron’s stock price fell to $686.36 per share on April\n29, 2026, a decline of about 6.2% in the span of just a single day. On May 15,\n2026, Regeneron issued a press release announcing that the “Phase 3 Trial of\nFianlimab . . . did not reach statistical significance for the primary\nendpoint of improvement in progression-free survival (PFS).” Following this\nnews, the price of Regeneron’s common stock declined even further. From a\nclosing market price of $698.25 per share on May 15, 2026, Regeneron’s stock\nprice fell to $629.68 per share on May 18, 2026, a decline of about 9.8% in\nthe span of one day.\n\nDEADLINE: September 14, 2026 Shareholders should not delay in registering for\nthis class action. Register your information here:\nhttps://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form-2/?id=195838&from=3 \n\nNEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased\nshares of REGN during the timeframe listed above, you will be enrolled in a\nportfolio monitoring software to provide you with status updates throughout\nthe lifecycle of the case. The deadline to seek to be a lead plaintiff is\nSeptember 14, 2026. There is no cost or obligation to you to participate in\nthis case.\n\nWHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action\nlaw firm, and our mission is to protect the rights of all investors who have\nsuffered as a result of deceit, fraud, and illegal business practices. The\nGross Law Firm is committed to ensuring that companies adhere to responsible\nbusiness practices and engage in good corporate citizenship. The firm seeks\nrecovery on behalf of investors who incurred losses when false and/or\nmisleading statements or the omission of material information by a company\nlead to artificial inflation of the company's stock. Attorney advertising.\nPrior results do not guarantee similar outcomes.\n\nCONTACT:\nThe Gross Law Firm\n15 West 38th Street, 12th floor\nNew York, NY, 10018\nEmail: dg@securitiesclasslaw.com \nPhone: (646) 453-8903\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0e447323-403e-415d-a0b4-846f2654a80f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXc0yjzC","title":"The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN","author":"Globe Newswire","ticker":"REGN","created":"2026-07-24T16:53:14.110Z","tickers":["REGN"],"exchange":"NASDAQ","article_body":"NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the\nfollowing notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ:\nREGN).\n\nShareholders who purchased shares of REGN during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointment.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCONTACT US HERE:\n\nhttps://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form-2/?id=195838&from=3 \n\nCLASS PERIOD: August 1, 2025 to May 15, 2026\n\nALLEGATIONS: According to the complaint, defendants provided overwhelmingly\npositive statements to investors while, at the same time, disseminating\nmaterially false and misleading statements and/or concealing material adverse\nfacts concerning the true state of Regeneron’s Phase III Fianlimab-Libtayo\nStudy; notably, that its preliminary statistical assumptions were\nfundamentally flawed, that the active treatment arm was failing to achieve\nmeaningful clinical differentiation over standard therapies, and that the\ntrial would ultimately fail to reach statistical significance on its primary\nendpoint even without overperformance of the control arm. On April 29, 2026,\nduring Regeneron’s first quarter earnings call, defendants disclosed the\nPhase III Fianlimab-Libtayo Study had been altered, expanding the number of\npatients in the study eligible for “analysis of progression-free\nsurvival.” Following this news, the price of Regeneron’s common stock\ndeclined dramatically. From a closing market price of $731.77 per share on\nApril 28, 2026, Regeneron’s stock price fell to $686.36 per share on April\n29, 2026, a decline of about 6.2% in the span of just a single day. On May 15,\n2026, Regeneron issued a press release announcing that the “Phase 3 Trial of\nFianlimab . . . did not reach statistical significance for the primary\nendpoint of improvement in progression-free survival (PFS).” Following this\nnews, the price of Regeneron’s common stock declined even further. From a\nclosing market price of $698.25 per share on May 15, 2026, Regeneron’s stock\nprice fell to $629.68 per share on May 18, 2026, a decline of about 9.8% in\nthe span of one day.\n\nDEADLINE: September 14, 2026 Shareholders should not delay in registering for\nthis class action. Register your information here:\nhttps://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form-2/?id=195838&from=3 \n\nNEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased\nshares of REGN during the timeframe listed above, you will be enrolled in a\nportfolio monitoring software to provide you with status updates throughout\nthe lifecycle of the case. The deadline to seek to be a lead plaintiff is\nSeptember 14, 2026. There is no cost or obligation to you to participate in\nthis case.\n\nWHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action\nlaw firm, and our mission is to protect the rights of all investors who have\nsuffered as a result of deceit, fraud, and illegal business practices. The\nGross Law Firm is committed to ensuring that companies adhere to responsible\nbusiness practices and engage in good corporate citizenship. The firm seeks\nrecovery on behalf of investors who incurred losses when false and/or\nmisleading statements or the omission of material information by a company\nlead to artificial inflation of the company's stock. Attorney advertising.\nPrior results do not guarantee similar outcomes.\n\nCONTACT:\nThe Gross Law Firm\n15 West 38th Street, 12th floor\nNew York, NY, 10018\nEmail: dg@securitiesclasslaw.com \nPhone: (646) 453-8903\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0e447323-403e-415d-a0b4-846f2654a80f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-24T16:53:14.152694924Z","server_sent_at_ms":1784911994152},"received_at":"2026-07-24T16:53:14.203Z","source_url":null},"analysis":{"id":"87177","press_release_id":"98138","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"The Gross Law Firm issued a shareholder-solicitation notice regarding Regeneron Pharmaceuticals (REGN); no new disclosure from the company itself.\n\nThe release alleges misleading statements about the Phase III Fianlimab-Libtayo Study and cites subsequent stock price declines in April and May 2026.\n\nThis is a routine lead-plaintiff-deadline reminder, not an issuer disclosure or a court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[],"products":["Fianlimab","Libtayo","Fianlimab-Libtayo Study"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"The Gross Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$731.77 per share","context":"closing market price on April 28, 2026"},{"amount":"$686.36 per share","context":"closing market price on April 29, 2026"},{"amount":"$698.25 per share","context":"closing market price on May 15, 2026"},{"amount":"$629.68 per share","context":"closing market price on May 18, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by The Gross Law Firm. No new disclosure from the issuer; no certified class, no settlement. Routine lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"REGN"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"The Gross Law Firm issued a shareholder-solicitation notice regarding Regeneron Pharmaceuticals (REGN); no new disclosure from the company itself.\n\nThe release alleges misleading statements about the Phase III Fianlimab-Libtayo Study and cites subsequent stock price declines in April and May 2026.\n\nThis is a routine lead-plaintiff-deadline reminder, not an issuer disclosure or a court action; treat as low-signal noise.","key_figures":{},"named_entities":{"people":[],"products":["Fianlimab","Libtayo","Fianlimab-Libtayo Study"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"The Gross Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$731.77 per share","context":"closing market price on April 28, 2026"},{"amount":"$686.36 per share","context":"closing market price on April 29, 2026"},{"amount":"$698.25 per share","context":"closing market price on May 15, 2026"},{"amount":"$629.68 per share","context":"closing market price on May 18, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-24T16:55:17.278Z","global_importance":10,"audience_relevance":15,"importance_components":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":59728,"modelName":"glm-4.7"}}